PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)
I'm LongbridgeAI, I can summarize articles.PharmaCyte Biotech reported no revenue for Q3 and YTD ending January 31, 2026, with a loss of $0.17 per share for the quarter and $2.41 for the nine months. Operating losses were $2.12 million for Q3 and $4.34 million YTD, attributed to increased administrative expenses. The company is actively engaging with the FDA regarding an IND clinical hold and is advancing its Cell-in-a-Box platform. It has secured private financing and is exploring strategic partnerships to support clinical development.
PharmaCyte Biotech reported no revenue for the three and nine months ended January 31, 2026, and posted a per-share loss of $0.17 for the quarter and $2.41 for the nine-month period. Operating losses were $2.12 million for the quarter and $4.34 million for the nine months, while net income reflected a $0.75 million gain for the quarter but a $15.03 million loss year-to-date after large fair value and noncash items. The company attributed the operating shortfall to increased general and administrative expenses and noted ongoing financing and strategic reviews to support clinical development activities.
Financial Highlights
- Revenue: $0.0 million — no revenue reported for the three and nine months ended January 31, 2026.
- Operating Income (Loss): $(2.12) million for the three months; $(4.34) million for the nine months, driven by increases in general and administrative expenses.
- Net Income (Loss): $0.75 million for the three months; $(15.03) million for the nine months, after large fair value and other noncash items.
- Net Income Per Share: $(0.17) basic and diluted for the three months; $(2.41) basic and diluted for the nine months.
Business Highlights
- Regulatory Progress: Active engagement with the FDA to address an IND clinical hold for locally advanced pancreatic cancer (LAPC); multiple nonclinical and CMC items have been completed and submissions are ongoing.
- Product Development: Continued advancement of the Cell-in-a-Box/CypCaps™ platform with studies on stability, sequencing, biocompatibility, and compatibility either underway or completed to support clinical readiness.
- Operational Shift: Company curtailed spending pending review by its Strategic Scientific Committee and Board; reengaged with SG Austria and is evaluating alternative prodrug/activator approaches to optimize development strategy.
- Capital and Partnerships: Secured private financings and pursued strategic partnerships, including work with QCLS and collection of a note from Femasys, to fund operations and clinical preparation efforts.
Original SEC Filing: PharmaCyte Biotech, Inc. [ PMCB ] - 10-Q - Mar. 17, 2026